The evidence of safety and efficacy from clinical trials supports the feasibility of selectively targeting FTH1 in cancer therapy, opening up new avenues for treatment strategies for KRAS-mutant pancreatic cancer. The gene discussed is FTH1; the disease is familial pancreatic carcinoma.